Zepbound package insert and carton labeling revised

The Food and Drug Administration's Drugs@FDA database lists a new supplement, S-020, for Zepbound's original approval (NDA 217806), with an action date of Feb. 7, 2025 ^[1]. The filing is categorized as "Labeling-Package Insert, Labeling-Container/Carton Labels," meaning it touched the printed prescribing information and the packaging text, not the drug's approved uses or clinical data ^[1].

Zepbound is the brand name for tirzepatide, made by Eli Lilly, and was first approved on Nov. 8, 2023 ^[1]. The drug is sold in a range of strengths from 2.5 mg to 60 mg, across single-dose vials, an autoinjector, and the KwikPen delivery device ^[1]. The FDA's database does not spell out the specific text that changed in this Feb. 7, 2025 update, so the exact nature of the revision, whether it involved storage instructions, warnings, dosing information, or something else, is not stated in the source and is not yet known from this record ^[1].

This labeling supplement followed a different kind of filing just weeks earlier. On Dec. 20, 2024, the FDA approved SUPPL-13, listed as an "Efficacy-New Indication" change, which added a new approved use for the drug ^[1]. That earlier filing changed what the drug is approved to treat. By contrast, the Feb. 7, 2025 filing is administrative in nature, updating the printed materials that accompany the product rather than its approved indications ^[1].

The same FDA record shows Zepbound's labeling has been revised repeatedly over time. Later entries in the database list additional package insert and Medication Guide updates in September 2025, a manufacturing and formulation change in January 2026, another round of container label, package insert, and Medication Guide updates in January 2026, a further package insert revision in February 2026, and an efficacy-related labeling change tied to new clinical data in August 2026 ^[1].

Why it matters for patients

FDA-approved labeling changes like this one can update safety information, instructions, or how information is presented on the box and insert that comes with a prescription, without altering what condition the drug is approved to treat. Because the source only classifies the type of submission and does not quote the revised text, patients cannot tell from this record alone what specific language changed in the Feb. 7, 2025 update ^[1].

For anyone filling a Zepbound prescription, the version of the package insert and Medication Guide dispensed with the medication reflects the most current approved labeling at the time of dispensing. Pharmacies and manufacturers are expected to use updated printed materials once a labeling supplement like this is approved, though the database entry does not describe a rollout timeline ^[1].

What happens next

According to the same FDA database entry, Zepbound's label was revised again on Sept. 25, 2025, and further changes followed in early 2026, including a manufacturing and formulation update on Jan. 7, 2026, and additional package insert, carton label, and Medication Guide changes on Jan. 20, 2026 and Feb. 25, 2026 ^[1]. A separate filing recorded on Aug. 26, 2026, is described as an efficacy-related labeling change tied to new clinical data, though the source does not detail what that data showed ^[1]. None of these later entries include a description of the specific content changed, so those details are not yet known from the available source.